The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-? to activate apoptosis

DOI: 10.1038/cddiscovery.2015.34
Cell Death Discovery, 2015, 1, 15034.

#	Paper	IF	Citations
20	Understanding drug-cytokine synergistic toxicity. *Cell Death and Disease*, **2015**, 6, e1988	9.8	
19	A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. *Investigational New Drugs*, **2016**, 34, 439-49	4.3	71
18	Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. *Blood Cancer Journal*, **2017**, 7, e520	7	26
17	NEDD8-activating enzyme inhibitor, MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis through up-regulation of ATF-4. *Biochemical and Biophysical Research Communications*, **2017**, 488, 1-5	3.4	11
16	Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	11
15	Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. *Blood*, **2018**, 131, 1415-1424	2.2	117
14	The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1 subgroup of multiple myeloma cells for TNF-induced cell death. *Cell Death and Disease*, **2019**, 10, 611	9.8	11
13	Asymmetric Synthesis of Fluoro-MLN4924 as a Selective NEDD8-Activating Enzyme (NAE) Inhibitor. *Asian Journal of Organic Chemistry*, **2019**, 8, 1641-1647	3	
12	An alternative and efficient synthesis of MLN4924, a selective NEDD8 inhibitor. *Organic Chemistry Frontiers*, **2019**, 6, 2480-2487	5.2	1
11	PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer. *Chemical Communications*, **2019**, 55, 2704-2707	5.8	53
10	Diverse and pivotal roles of neddylation in metabolism and immunity. *FEBS Journal*, **2021**, 288, 3884-3912	5.7	16
9	Perspectives on the Clinical Development of NRF2-Targeting Drugs. *Handbook of Experimental Pharmacology*, **2021**, 264, 93-141	3.2	11
8	What have we learned from animal models of idiosyncratic, drug-induced liver injury?. *Expert Opinion on Drug Metabolism and Toxicology*, **2020**, 16, 475-491	5.5	1
7	Phase I study assessing the mass balance, pharmacokinetics, and excretion of [C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. *Investigational New Drugs*, **2021**, 39, 488-498	4.3	4
6	A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors. *Investigational New Drugs*, **2021**, 39, 1036-1046	4.3	2
5	The Effect of Neddylation Inhibition on Inflammation-Induced MMP9 Gene Expression in Esophageal Squamous Cell Carcinoma. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
4	Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms. *Frontiers in Immunology*, **2021**, 12, 683401	8.4	11

3	Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis. *Oncotarget*, **2017**, 8, 21128-21139	3.3	8
2	Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. **2022**, 40, 1042-1050		0
1	Hepatic neddylation deficiency triggers fatal liver injury via inducing NF-B-inducing kinase in mice. **2022**, 13,		0